Sign Up to Receive Your Personalised Learning Resources
CONFERENCE HUB
Suman Kushwaha, MDS 2022: Neurological symptoms and COVID-19 vaccination
Start Learning
A patient’s perspective: Best practice for shared decision making in the prevention and treatment of migraine
Rajeev Kumar, MDS 2022: ANX005, a humanized monoclonal antibody for Huntington’s disease, the phase 2 study results
Angelo Antonini, EAN 2022: Update on disease-modifying treatments in Parkinson’s disease
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
touchTEAMS EXAMPLE ONLY *title here*
Bruce Cree, AAN 2022: Disability improvements with ublituximab in relapsing multiple sclerosis – Phase 3 ULTIMATE I and II trials
Updates in Paediatric Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Amy Gelfand: COVID-19 Vaccines and Their Impact on Migraine Treatment
Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis
Foreword – touchREVIEWS in Neurology, Volume 18, Issue 2, 2022
Sign up to view Favourites, Keep Notes and Track CME Credits
Favourites
Integrating practice to enhance care of patients with multiple sclerosis
View
Considering the complete picture in neuromyelitis optica spectrum disorder: Optimizing diagnosis and management to improve patient outcomes
View
Assessment and Treatment of Myoclonus: A Review
View
Severe Cytomegalovirus Encephalomyelitis and Polyradiculitis in the Immunocompetent: An Unusual Case of Critical Illness
View
James Howard AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial
View
Claire Sexton: Highlights of AAIC 2022
View
Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis
View
Nina Muirhead: Impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life of family members – Results of an online survey
View
Esther Cubo, MDS 2022: Insulin-like growth factor-1 and social cognition in Huntington’s disease
View
Foreword – touchREVIEWS in Neurology, Volume 18, Issue 1, 2022
View